Skip to content

A Clinical Study of Mesenchymal Progenitor Cell Exosomes Nebulizer for the Treatment of ARDS

A Phase I Clinical Study on the Safety and Efficacy of Allogeneic Human Adipose-derived Mesenchymal Stem Cell Exosomes (haMSC-Exos) Nebulized Inhalation in the Treatment of Moderate to Severe Acute Respiratory Distress Syndrome (ARDS)

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000035771
Enrollment
Unknown
Registered
2020-08-16
Start date
2020-09-01
Completion date
Unknown
Last updated
2020-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Respiratory Distress Syndrome

Interventions

haMSC-Exos low-dose group:7 times aerosol inhalation of haMSC-Exos (2.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
haMSC-Exos medium-dose group:7 times aerosol inhalation of haMSC-Exos (8.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)
haMSC-Exos high-dose group:7 times aerosol inhalation of haMSC-Exos (16.0*108 nano vesicles/3 ml at Day 1, Day 2, Day 3, Day 4, Day 5, Day 6, Day 7)

Sponsors

Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. The subjects themselves or their family members voluntarily participate in this study and sign the informed consent form; 2. aged 18-70 years old, male or female; 3. Definitely diagnosed as acute respiratory distress syndrome (ARDS) (according to the Berlin definition and diagnostic criteria of ARDS); 4. Course of disease =8 cmH2O; Severe: PaO2/FiO2 =10 cmH2O. Chest X-ray showed bilateral infiltration with pulmonary edema; no clinical manifestations of left ventricular hypertension, or pulmonary artery wedge pressure (PAOP) =18mmHg.

Exclusion criteria

Exclusion criteria: 1. Patients with severe allergic constitution; 2. Moderate to severe liver failure (children Pugh score > 12); 3. Patients with severe chronic respiratory diseases, PaCO2 > 50mmhg, and need home oxygen therapy; 4. Severe trauma occurred within 14 days before screening; 5. History of malignant tumor (patients with skin basal cell carcinoma in the past can be included); 6. They are undergoing hemodialysis or peritoneal dialysis; 7. The patients who had deep venous thrombosis or pulmonary embolism within 90 days; 8. Acute myocardial infarction occurred within 30 days; 9. Neuromuscular diseases that result in impaired natural ventilation include, but are not limited to, C5 or higher spinal cord injury, amyotrophic lateral sclerosis, Guillain Barre syndrome, and myasthenia gravis; 10. Obesity (BMI > 28); 11. Lung transplantation; 12. Bone marrow transplantation; 13. Active immunosuppression is defined as receiving immunosuppressive drugs or having a medical condition associated with immunodeficiency. These included: 1) HIV (AIDS or CD4 40). Results: short term systemic steroid therapy (intravenous or oral) for less than 1 week, topical steroid for skin diseases; 4) absolute neutrophil count < 500 / mm3; 14. Patients undergoing extracorporeal circulation support (ECMO) or high frequency oscillatory ventilation; 15. They were not willing to receive lung protective ventilation (minimum tidal volume 6ml / kg pbw) or liquid management treatment; 16. Have a history of epilepsy, need continuous anticonvulsant therapy, or have received anticonvulsant therapy in the past 3 years; 17. The estimated survival time was less than 30 days; 18. Hepatitis B, hepatitis C, AIDS, syphilis patients; 19. Women of childbearing age are pregnant, lactating or pregnant within one year; 20. Those who could not understand the study protocol; according to the judgment of the researchers, there were other situations in which the patients were not suitable to participate in the study (for example, there were factors to reduce the follow-up compliance, and the patients did not receive relevant supportive treatment, etc.).

Design outcomes

Primary

MeasureTime frame
Adverse Drug Reaction;

Secondary

MeasureTime frame
Murray lung injury score;PaO2/FiO2;SOFA score;Number of deaths;The number of days that survivors were offline for mechanical ventilation;The number of days the survivor was out of ICU;Treatment Emergent Adverse Event;

Countries

China

Contacts

Public ContactJieming Qu

Ruijin Hospital affiliated Shanghai Jiao Tong University School of Medicine

jmqu0906@163.com+86 21-64370045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026